Effect of Imipenem and Meropenem on the Digestive Microbiota and the Emergence and Carriage of Multidrug-resistant Bacteria
Launched by FONDATION HÔPITAL SAINT-JOSEPH · Aug 23, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how two antibiotics, imipenem and meropenem, affect the gut bacteria of patients with infections caused by certain resistant bacteria called Enterobacteriaceae. These bacteria have become a significant health concern because they are hard to treat and can lead to serious complications. The goal of the study is to compare how these two antibiotics impact the diversity of bacteria in the digestive system and the emergence of multidrug-resistant bacteria, which are bacteria that have become resistant to multiple treatments.
To take part in this trial, participants must be at least 18 years old, currently hospitalized in the intensive care unit at one of the participating hospitals, and require treatment with either imipenem or meropenem for their infection. Participants will be monitored to see how their gut bacteria respond to the antibiotic they receive. It’s important to note that individuals with allergies to carbapenems, pregnant or breastfeeding women, and certain other groups may not be eligible for this study. This research could help improve our understanding of how to use antibiotics more effectively while minimizing the risk of developing resistant bacteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient ≥ 18 years old
- • Patient hospitalized in the intensive care unit of the Groupe Hospitalier Paris Saint-Joseph or the Avicenne Hospital
- • Patient with an infection requiring probabilistic or documented treatment with a carbapenem (imipenem or meropenem)
- • French speaking patient
- • Patient or relative able to give his or her non-objection
- Exclusion Criteria:
- • Patients with a carbapenem allergy
- • Pregnant or breastfeeding woman
- • Patient under guardianship or curatorship
- • Patient deprived of liberty
- • Patient under court protection
About Fondation Hôpital Saint Joseph
Fondation Hôpital Saint-Joseph is a dedicated clinical trial sponsor committed to advancing healthcare and improving patient outcomes through innovative research. Located in a reputable healthcare institution, the foundation collaborates with healthcare professionals and researchers to conduct high-quality clinical trials across various medical fields. By fostering a culture of scientific excellence and patient-centered care, Fondation Hôpital Saint-Joseph aims to contribute valuable insights to the medical community and enhance the quality of treatments available to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bobigny, , France
Paris, , France
Patients applied
Trial Officials
Benoit PILMIS, MD
Principal Investigator
Fondation Hôpital Saint-Joseph
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials